Full Text View
Tabular View
No Study Results Posted
Related Studies
Is There is a Role of Prophylactic Therapy With Tamsulosin Before Extracorporeal Shock Wave Lithotripsy to Avoid Development of Steinstrasse ?
This study is currently recruiting participants.
Verified by HaEmek Medical Center, Israel, June 2007
First Received: June 19, 2007   Last Updated: June 20, 2007   History of Changes
Sponsor: HaEmek Medical Center, Israel
Information provided by: HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier: NCT00489723
  Purpose

The purpose of this study is to determine if there is a role of prophylactic therapy with tamsulosin prior extracorporeal shock wave lithotripsy to avoid development of steinstrasse. 150 persons that will go to Extracorporeal shock wave lithotripsy will randomize to 2 groups.

Group 1 -of 75 persons will recieve tamsulosin 0.4 mg x 1/d 2 days before the lithotripsy .

Group 2 - of 75 persons will not recieve tamsulosin. 48 hour after the ESWL all 2 group will take abdominal radiograph to evaluate the presence of steinstrasse.


Condition Intervention
Kidney Stones
Drug: tamsulosin 0.4mg

Study Type: Observational
Study Design: Screening, Longitudinal, Defined Population, Prospective Study

Resource links provided by NLM:


Further study details as provided by HaEmek Medical Center, Israel:

Study Start Date: May 2007
  Eligibility

Ages Eligible for Study:   15 Years to 85 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • size of stone 1-2 cm

Exclusion Criteria:

  • ureteral stricture Presence of internal stent prior use of alfa bloker prior ESWL
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00489723

Contacts
Contact: DORON PEREZ, M.D. +972-4-6495115 perez_do@clalit.org.il

Locations
Israel
Haemek medical center Recruiting
afula, Israel, 18100
Contact: DORON PEREZ, M.D.     +972-4-6495115     perez_do@clalit.org.il    
Principal Investigator: doron perez, M.D.            
Sponsors and Collaborators
HaEmek Medical Center, Israel
Investigators
Principal Investigator: doron perez Urology department: Haemek Medical Center
  More Information

No publications provided

Study ID Numbers: 0056-07-EMC
Study First Received: June 19, 2007
Last Updated: June 20, 2007
ClinicalTrials.gov Identifier: NCT00489723     History of Changes
Health Authority: Israel: Ethics Commission

Keywords provided by HaEmek Medical Center, Israel:
size of stone 1-2 cm
Pt. with no use of alfa bloker prior ESWL
Pt. without internal stent

Additional relevant MeSH terms:
Pathological Conditions, Anatomical
Urinary Calculi
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Antineoplastic Agents
Urolithiasis
Physiological Effects of Drugs
Adrenergic alpha-Antagonists
Calculi
Pharmacologic Actions
Urologic Diseases
Therapeutic Uses
Tamsulosin
Adrenergic Antagonists
Kidney Diseases
Nephrolithiasis
Kidney Calculi

ClinicalTrials.gov processed this record on February 08, 2010